Site menu:
General information
Personalized medicine holds great promise for cancer treatment. One of the unfolding success stories is the use of PARP inhibitors in hereditary
breast and ovarian tumors. Various other approaches that also target DNA damage response defects in tumors are in development in preclinical or early
clinical tests. This meeting brings together preclinical and clinical researchers working on PARP inhibitor treatment and similar approaches.
The meeting will start in the afternoon of January 26 at the Heineken Experience in Amsterdam with an afternoon focusing on the history and promises
of PARP inhibitor treatment. After this session, there will be plenty of time to network and discuss science during the drinks and dinner at the
same location. On January 27 and 28 the various aspects of PARP inhibitors and other DNA damage response modulators will be discussed. We will
discuss both basic biology and clinical application of DNA damage response modulation in tumor biology. We aim for a meeting of approximately
100 participants in a highly interactive atmosphere.
Members of the EU consortium DDResponse can participate free of charge, while outside participants will pay a € 100 registration fee, which includes
all drinks, lunches and the walking dinner on Monday evening. The conference venue can easily be reached via the Amsterdam central railway station,
which has a direct connection to Schiphol international airport. The meeting will end by lunch time on Wednesday to allow participants to fly back
home on the same day.
Organized by DDResponse. Organizing committee: Jan Hoeijmakers, Dik van Gent and Roland Kanaar (Rotterdam, The Netherlands).